[ad_1]
Indian investors appear to have been rattled by President Trump’s letters to global pharmaceutical companies demanding reduced drug prices. Industry experts believe this may be far fetched anticipating limited impact on Indian generic drugmakers.
The Indian pharma sector took a sharp hit on Friday, August 1 as US President Donald Trump’s aggressive demand for drug price cuts rattled markets already reeling from a 25% tariff shock. Major pharma exporters saw their shares plunge, dragging the Nifty Pharma index down over 3%, underscoring fears over their vulnerability to the US pricing crackdown.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Interaction with CNBC-TV18’s journalists
Webinars & LIVE Q&As with India Inc. Leaders
Exclusive CNBC-TV18 studio & newsroom tours
Premium business insights, expert opinions & analysis
Curated lifestyle privileges & offers
[ad_2]
Source link